Petr Kulišt’ák
Research Subjects
Petr Kulišt’ák has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Petr Ridzoň
Department of Neurology, Thomayer Teaching Hospital and Institute for Postgraduate Education in Medicine, Prague, Czech Republic
3 shared publications - Robert Rusina
Department of Neurology, Thomayer Teaching Hospital and Institute for Postgraduate Education in Medicine, Prague, Czech Republic
3 shared publications - Edvard Ehler
Neurol Klin FZS UP, Kyjevska 44, Pardubice 53203, Czech Republic
2 shared publications H. Klajblová
First Department of Neurology, Masaryk University, St Anne's Teaching Hospital, Brno, Czech Republic
2 shared publicationsI. Rektor
First Department of Neurology, Masaryk University, St Anne's Teaching Hospital, Brno, Czech Republic
2 shared publications- Irena Rektorova
Applied Neuroscience Research Group, Central European Institute of Technology – CEITEC, Masaryk University, Brno, Czech Republic
2 shared publications
Latest Publications
- 1 December 2013
- Published by Wolters Kluwer Health in Cognitive and Behavioral Neurology
- Vol. 26 (4) , 189-194
Pick and Alzheimer Diseases
We describe a patient with corticobasal syndrome in whom neuropathological examination on autopsy revealed Pick and Alzheimer diseases in comorbidity. Corticobasal degeneration is a tauopathy usually associated with asymmetric parkinsonism, parietal lobe involvement, and cognitive impairment. Corticobasal syndrome is the clinical presentation of corticobasal degeneration without neuropathological confirmation. A 66-year-old right-handed man slowly developed speech difficulties, right-hand clumsiness, and forgetfulness. His speech apraxia progressed to mutism with preserved comprehension, and his clumsiness progressed to severe apraxia involving both hands. He developed behavioral changes and severe amnesia. All of these features were consistent with corticobasal syndrome. His loss of episodic, verbal, and visuospatial memory suggested Alzheimer disease; however, beyond his frontotemporal neuropsychological profile, he had few symptoms characteristic of frontal lobe dementia. Magnetic resonance imaging scans showed worsening temporal, frontal, and parietal atrophy, predominant in the left hemisphere. Neuropathological examination at autopsy revealed abundant neuritic plaques and neurofibrillary tangles consistent with fully developed Alzheimer disease, as well as numerous intraneuronal Pick bodies in the frontotemporal lobes. Our findings confirm the importance of clinical and neuropathological correlations in patients with atypical neurodegenerative dementias.
- 1 December 2013
- Published by Wolters Kluwer Health in Cognitive and Behavioral Neurology
- Vol. 26 (4) , 189-194
Pick and Alzheimer Diseases
We describe a patient with corticobasal syndrome in whom neuropathological examination on autopsy revealed Pick and Alzheimer diseases in comorbidity. Corticobasal degeneration is a tauopathy usually associated with asymmetric parkinsonism, parietal lobe involvement, and cognitive impairment. Corticobasal syndrome is the clinical presentation of corticobasal degeneration without neuropathological confirmation. A 66-year-old right-handed man slowly developed speech difficulties, right-hand clumsiness, and forgetfulness. His speech apraxia progressed to mutism with preserved comprehension, and his clumsiness progressed to severe apraxia involving both hands. He developed behavioral changes and severe amnesia. All of these features were consistent with corticobasal syndrome. His loss of episodic, verbal, and visuospatial memory suggested Alzheimer disease; however, beyond his frontotemporal neuropsychological profile, he had few symptoms characteristic of frontal lobe dementia. Magnetic resonance imaging scans showed worsening temporal, frontal, and parietal atrophy, predominant in the left hemisphere. Neuropathological examination at autopsy revealed abundant neuritic plaques and neurofibrillary tangles consistent with fully developed Alzheimer disease, as well as numerous intraneuronal Pick bodies in the frontotemporal lobes. Our findings confirm the importance of clinical and neuropathological correlations in patients with atypical neurodegenerative dementias.
- Open Access
- 15 March 2011
- Published by Springer Nature in Magnetic Resonance Materials in Physics, Biology and Medicine
- Vol. 24 (2) , 67-76
Quantitative brain MR imaging in amyotrophic lateral sclerosis
To evaluate the potential of quantitative MR techniques [voxel-based morphometry (VBM), T2-relaxometry, mean diffusivity (MD), fractional anisotropy (FA)] in the diagnostics of amyotrophic lateral sclerosis (ALS). Thirty-three ALS patients and thirty age- and sex-matched healthy volunteers were included in the cross-sectional study. T1WI, T2WI and T2 relaxometry sequences were performed at 1.5T. DWI was performed in a subgroup of 12 patients. Disease severity was estimated with the ALS Functional Rating Scale (ALS-FRS). We detected decreased T2 relaxation rate (R2) in the frontal white matter (FWM) (left and right P < 0.005) and caudate nucleus (left P < 0.005) in ALS patients. R2 in the FWM correlated with age in patients and controls. A correlation (P < 0.01, cluster-level corrected) between atrophy in the corona radiata and the limb ALS-FRS subset was found, as well as a difference between patients and controls in this area. No correlation between FA/MD and ALS-FRS was observed in the T2 hyperintense region of the posterior limb of the internal capsule (PLIC), or in the site of atrophy detected by VBM. No R2 or PD changes in the PLIC were detected. TBSS revealed decreased FA in the corona radiata and callosal body. Decreased R2 in the left caudate and bilateral FWM may help in the diagnostic process and disqualifies these regions as internal controls in ALS studies. The PLIC is not a reliable diagnostic marker of ALS.
- 15 March 2011
- Published by Springer Nature in Magnetic Resonance Materials in Physics, Biology and Medicine
- Vol. 24 (2) , 67-76
Open AccessQuantitative brain MR imaging in amyotrophic lateral sclerosis
To evaluate the potential of quantitative MR techniques [voxel-based morphometry (VBM), T2-relaxometry, mean diffusivity (MD), fractional anisotropy (FA)] in the diagnostics of amyotrophic lateral sclerosis (ALS). Thirty-three ALS patients and thirty age- and sex-matched healthy volunteers were included in the cross-sectional study. T1WI, T2WI and T2 relaxometry sequences were performed at 1.5T. DWI was performed in a subgroup of 12 patients. Disease severity was estimated with the ALS Functional Rating Scale (ALS-FRS). We detected decreased T2 relaxation rate (R2) in the frontal white matter (FWM) (left and right P < 0.005) and caudate nucleus (left P < 0.005) in ALS patients. R2 in the FWM correlated with age in patients and controls. A correlation (P < 0.01, cluster-level corrected) between atrophy in the corona radiata and the limb ALS-FRS subset was found, as well as a difference between patients and controls in this area. No correlation between FA/MD and ALS-FRS was observed in the T2 hyperintense region of the posterior limb of the internal capsule (PLIC), or in the site of atrophy detected by VBM. No R2 or PD changes in the PLIC were detected. TBSS revealed decreased FA in the corona radiata and callosal body. Decreased R2 in the left caudate and bilateral FWM may help in the diagnostic process and disqualifies these regions as internal controls in ALS studies. The PLIC is not a reliable diagnostic marker of ALS.
- 18 December 2009
- Published by Wiley in European Journal of Neurology
- Vol. 17 (1) , 23-30
Relationship between ALS and the degree of cognitive impairment, markers of neurodegeneration and predictors for poor outcome. A prospective study
Introduction: Amyotrophic lateral sclerosis (ALS) is a common neurodegenerative disease affecting motor neurons and may be associated with impaired cognition. Reliable prognostic factors for ALS patients are still missing.Methods: We prospectively included 67 patients, 42 women and 25 men, with clinically defined ALS. The disease severity was assessed and the patients underwent SPECT, lumbar puncture with determination of tau, hyperphosporylated tau (p‐tau) and beta‐amyloid and a detailed neuropsychological assessment using a standardized test battery. In patients who died, a detailed neuropathologic evaluation was performed.Results: The mean survival duration was 26.8 months. The delay between the first signs and confirmation of the diagnosis was 12.75 months. Cognitive impairment did not have an impact on the evolution of the disease. There was no correlation between neuropsychological and SPECT findings. Higher age at onset, more pronounced handicap and elevated beta‐amyloid in the CSF were associated with shorter survival times. In brain tissue from nine of the deceased patients with ALS and dementia, all showed signs of comorbidity, six had hallmarks of frontotemporal lobar degeneration (FTLD) and three showed Alzheimer disease pathology. Brain tissues form 11 deceased ALS patients who did not show signs of dementia, had only changes compatible with a diagnosis of motor neuron disease.Conclusion: In our prospective study, age, disease severity and CSF beta‐amyloid levels taken together were a risk factor suggesting shorter survival times. Dementia is relatively frequent in ALS and may be a consequence of either FTLD or result from co‐existing Alzheimer disease.
- 18 December 2009
- Published by Wiley in European Journal of Neurology
- Vol. 17 (1) , 23-30
Relationship between ALS and the degree of cognitive impairment, markers of neurodegeneration and predictors for poor outcome. A prospective study
Introduction: Amyotrophic lateral sclerosis (ALS) is a common neurodegenerative disease affecting motor neurons and may be associated with impaired cognition. Reliable prognostic factors for ALS patients are still missing.Methods: We prospectively included 67 patients, 42 women and 25 men, with clinically defined ALS. The disease severity was assessed and the patients underwent SPECT, lumbar puncture with determination of tau, hyperphosporylated tau (p‐tau) and beta‐amyloid and a detailed neuropsychological assessment using a standardized test battery. In patients who died, a detailed neuropathologic evaluation was performed.Results: The mean survival duration was 26.8 months. The delay between the first signs and confirmation of the diagnosis was 12.75 months. Cognitive impairment did not have an impact on the evolution of the disease. There was no correlation between neuropsychological and SPECT findings. Higher age at onset, more pronounced handicap and elevated beta‐amyloid in the CSF were associated with shorter survival times. In brain tissue from nine of the deceased patients with ALS and dementia, all showed signs of comorbidity, six had hallmarks of frontotemporal lobar degeneration (FTLD) and three showed Alzheimer disease pathology. Brain tissues form 11 deceased ALS patients who did not show signs of dementia, had only changes compatible with a diagnosis of motor neuron disease.Conclusion: In our prospective study, age, disease severity and CSF beta‐amyloid levels taken together were a risk factor suggesting shorter survival times. Dementia is relatively frequent in ALS and may be a consequence of either FTLD or result from co‐existing Alzheimer disease.
- 25 June 2007
- Published by Wiley in European Journal of Neurology
- Vol. 14 (7) , 815-818
Amyotrophic lateral sclerosis and Alzheimer's disease – clinical and neuropathological considerations in two cases
Amyotrophic lateral sclerosis (ALS) may be accompanied by cognitive impairment; when present, it is mainly in the form of frontotemporal impairment. We report on two cases with clinically defined ALS that subsequently developed dementia. Neuropathological examination showed not only the typical neuropathological hallmarks characteristic of ALS but, surprisingly, also showed neurofibrillary tangles and neuritic plaques in sufficient numbers to fulfill the diagnostic criteria of definite Alzheimer's disease.
- 25 June 2007
- Published by Wiley in European Journal of Neurology
- Vol. 14 (7) , 815-818
Amyotrophic lateral sclerosis and Alzheimer's disease – clinical and neuropathological considerations in two cases
Amyotrophic lateral sclerosis (ALS) may be accompanied by cognitive impairment; when present, it is mainly in the form of frontotemporal impairment. We report on two cases with clinically defined ALS that subsequently developed dementia. Neuropathological examination showed not only the typical neuropathological hallmarks characteristic of ALS but, surprisingly, also showed neurofibrillary tangles and neuritic plaques in sufficient numbers to fulfill the diagnostic criteria of definite Alzheimer's disease.
- 21 December 2004
- Published by Wiley in European Journal of Neurology
- Vol. 12 (1) , 9-15
Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add‐on to l‐dopa therapy
In a randomized prospective multi‐centre study, we evaluated the cognitive performances of a group of 41 non‐demented patients, all with advanced Parkinson's disease (PD) and a current depressive episode, in whom the effects of pramipexole (PPX) and pergolide (PRG) in an add‐on to l‐dopa therapy were also studied and published with regard to motor symptoms of PD, motor complications and depression. The Trail Making Test, the Stroop test and four subtests (arithmetic, picture completion, digit symbols and similarities) of the Wechsler Adult Intelligence Scale‐Revised were performed prior to and 8 months after the administration of either PPX or PRG. We found no statistically significant difference between the two tested drugs or between the first and the last visit in any of the above‐listed neuropsychological tests. All patients’ motor outcomes significantly improved and we conclusively demonstrated the anti‐depressive effect of PPX. The dissociation of dopaminomimetic effects on the different tested domains indicates that there are different pathological mechanisms of cognitive, motor and affective disturbances in advanced PD patients. In our non‐demented group of fluctuating depressed PD subjects, both PPX and PRG administration in combination with l‐dopa were safe in terms of the effect on cognitive performance.
- 21 December 2004
- Published by Wiley in European Journal of Neurology
- Vol. 12 (1) , 9-15
Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add‐on to l‐dopa therapy
In a randomized prospective multi‐centre study, we evaluated the cognitive performances of a group of 41 non‐demented patients, all with advanced Parkinson's disease (PD) and a current depressive episode, in whom the effects of pramipexole (PPX) and pergolide (PRG) in an add‐on to l‐dopa therapy were also studied and published with regard to motor symptoms of PD, motor complications and depression. The Trail Making Test, the Stroop test and four subtests (arithmetic, picture completion, digit symbols and similarities) of the Wechsler Adult Intelligence Scale‐Revised were performed prior to and 8 months after the administration of either PPX or PRG. We found no statistically significant difference between the two tested drugs or between the first and the last visit in any of the above‐listed neuropsychological tests. All patients’ motor outcomes significantly improved and we conclusively demonstrated the anti‐depressive effect of PPX. The dissociation of dopaminomimetic effects on the different tested domains indicates that there are different pathological mechanisms of cognitive, motor and affective disturbances in advanced PD patients. In our non‐demented group of fluctuating depressed PD subjects, both PPX and PRG administration in combination with l‐dopa were safe in terms of the effect on cognitive performance.
- 19 June 2003
- Published by Wiley in European Journal of Neurology
- Vol. 10 (4) , 399-406
Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study
An 8‐month multicentre prospective randomized study aimed at comparing the effects of dopamine receptor agonists pramipexole (PPX; Mirapexin®) and pergolide (PRG; Permax®) as add‐on to L‐dopa therapy on depression [Montgomery and Asberg Depression Rating Scale (MADRS)] in 41 non‐demented patients (25 men, 16 women) suffering from both mild or moderate depression and advanced Parkinson's disease (PD). The assessment was performed by a blinded independent observer. Motor symptoms (UPDRS III), motor complications (UPDRS IV), activities of daily living (UPDRS II and VI) and depressive symptoms as measured by Self – Rating Depression Scale by Zung were evaluated in an open‐label design.The average value of Zung scores decreased significantly in both groups with no statistical difference between both groups. A significant decrease in the average value of MADRS scores was present only in the PPX group. The average UPDRS scores decreased significantly with no statistical difference between both groups at the comparable average total daily dose of both preparations. In both cases, the total daily dose of L‐dopa decreased significantly but the decrease was statistically more pronounced in the PRG group.Our results demonstrate the antidepressant effect of PPX in patients with PD while we can't make any conclusions with regard to antidepressant effect of PRG.
- 19 June 2003
- Published by Wiley in European Journal of Neurology
- Vol. 10 (4) , 399-406
Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study
An 8‐month multicentre prospective randomized study aimed at comparing the effects of dopamine receptor agonists pramipexole (PPX; Mirapexin®) and pergolide (PRG; Permax®) as add‐on to L‐dopa therapy on depression [Montgomery and Asberg Depression Rating Scale (MADRS)] in 41 non‐demented patients (25 men, 16 women) suffering from both mild or moderate depression and advanced Parkinson's disease (PD). The assessment was performed by a blinded independent observer. Motor symptoms (UPDRS III), motor complications (UPDRS IV), activities of daily living (UPDRS II and VI) and depressive symptoms as measured by Self – Rating Depression Scale by Zung were evaluated in an open‐label design.The average value of Zung scores decreased significantly in both groups with no statistical difference between both groups. A significant decrease in the average value of MADRS scores was present only in the PPX group. The average UPDRS scores decreased significantly with no statistical difference between both groups at the comparable average total daily dose of both preparations. In both cases, the total daily dose of L‐dopa decreased significantly but the decrease was statistically more pronounced in the PRG group.Our results demonstrate the antidepressant effect of PPX in patients with PD while we can't make any conclusions with regard to antidepressant effect of PRG.